ClinicalTrials.gg
CompletedNCT03731897Updated Jun 18, 2020

Evaluation of the Efficacy of Prolotherapy Treatment in Patients With Plantar Fasciitis: a Randomized Double-blind Study

An interventional study of 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. and 9 cc salin + 1cc 2% lidocaine. in Plantar Fascitis, sponsored by Ankara Education and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-18.

Sponsored by Ankara Education and Research Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Plantar fasciitis is the most common cause of heel pain and it is diagnosed by clinically.

Resting, stretching exercises, weight loss, nonsteroidal anti-inflammatory drugs and physical therapy methods are used in the treatment. Steroid injection can be applied in patients who do not respond to these treatments. But steroid injection is not a pathology-based treatment, and also can cause serious side effects, such as fat pad atrophy and plantar fascia rupture. At this stage, in patients who do not respond to conservative treatments, new methods such as dextrose prolotherapy and platelet rich plasma may be used instead of steroid injection. In the literature, there is insufficient study showing effect of prolotherapy in patients with plantar fasciitis. Because these studies enrolled small number of patients and lacked controlled design. The investigators design a randomized, double-blind, controlled trial to assess the effect after prolotherapy injection in patients with plantar fasciitis.

The participants evaluated with clinically and sonographically. The aim of this study is to compare the pain, function and thickness of proximal plantar fascia in prolotherapy or control group.

Read the detailed description

After obtaining written informed consent, patients of clinically and sonographically diagnosed with plantar fasciitis were randomized into intervention and control group. Participants in intervention group received two-session prolotherapy injection and control group received two-session 9cc salin + 1 cc 2% lidocaine injection in 3 weeks interval. Stretching and range of motion exercises were prescribed after treatment.

The primary outcome is visual analog scale (VAS) and secondary outcomes include Foot Function Index , ultrasonographic measurement of proximal plantar fascia. The evaluation was performed pretreatment as well as on the 1st and 3th month the treatment.

02

Conditions studied

  • Plantar Fascitis
03

In context

Lead sponsor

Ankara Education and Research Hospital is the lead sponsor of 14 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18-65 year-old.
  • Heel pain for at least 3 months
  • Plantar fasciitis which diagnosed clinically and confirmed using ultrasonography (plantar fascia thickness > 4mm)

Exclusion criteria

Exclusion Criteria:

  • History of chronic pain syndromes
  • Patients undergoing injections for the treatment of plantar fasciitis in the last 6 months
  • Rheumatic diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    prolotherapy

    Experimental: Plantar fasciitis injection with prolotherapy total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone. Drug: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine. This treatment, known as regenerative injection therapy, stimulates tissue repair and reduces pain.

    Other: 5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.

  • Placebo comparator
    control

    Placebo Comparator: Plantar fasciitis injection with 9cc salin + 1 cc 2% lidocaine total 5cc. Procedure: Plantar fascia will be injected to the places where it adheres to the bone. Drug: 9 cc salin + 1cc 2% lidocaine. This treatment is safe for Plantar fasciitis injection.

    Other: 9 cc salin + 1cc 2% lidocaine.

Interventions

  • Other5 cc 30% dextrose + 4 cc salin + 1cc 2% lidocaine.

    Plantar fascia will be injected to the places where it adheres to the bone.

  • Other9 cc salin + 1cc 2% lidocaine.

    Plantar fascia will be injected to the places where it adheres to the bone.

06

What researchers measure

Primary outcomes

  1. Change from baseline of pain on 1st and 3th months after treatment: VAS

    Using the Visual analog scale (VAS) to measure the pain scale before treatment and multiple time frame after treatment. Recorded on a visual analogue scale (VAS), scores range from 0 to 100 mm, with higher scores indicating worse pain.

    Time frame: Pre-treatment, 1st and 3th months after treatment

Secondary outcomes

  1. Change from baseline in activity and functional status on 1st and 3th months after treatment.

    Using the Foot Function Index (FFI) to measure the activity and functional status before treatment and multiple time frame after treatment. . The FFI consists of 23 self-reported items divided into 3 subcategories on the basis of patient values: pain, disability and activity limitation. The patient has to score each question on a scale from 0 (no pain or difficulty) to 10 (worst pain imaginable or so difficult it requires help), that best describes their foot over the past week. The higher scores indicate worse pain. Both total and subcategory scores are calculated.

    Time frame: Pre-treatment, 1st and 3th months after treatment

  2. Change from baseline in thickness of proximal plantar fascia on 1st and 3th months after treatment.

    Using the musculoskeletal sonogram to measure the proximal plantar fascia thickness.

    Time frame: Pre-treatment, 1st and 3th months after treatment treatment

07

Study locations

1 site
  • Basak Mansiz-Kaplan
    Ankara, 06230, Turkey
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2018 to primary completion in Mar 2019, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2018
First posted
Nov 6, 2018
StartActual
Nov 12, 2018
Primary completionActual
Mar 12, 2019
CompletionActual
Jun 12, 2019
Last update
Jun 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03731897
Lead sponsor
Ankara Education and Research Hospital
Responsible party
Basak Mansiz-Kaplan (Department of Physical Medicine and Rehabilitation, Ankara Education and Research Hospital) — Principal investigator
First posted
Nov 6, 2018
Start date
Nov 12, 2018
Primary completion
Mar 12, 2019
Completion
Jun 12, 2019
Last update
Jun 18, 2020

Study contacts

Basak Mansiz-Kaplan
principal investigator · Physical Medicine and Rehabilitation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion